Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex ships Canada's first drugs under TRIPS

This article was originally published in Scrip

Executive Summary

The Canadian company Apotexhas shipped seven million tablets of its HIV/AIDS triple combination drug Apo-TriAvir (zidovudine, lamivudine plus nevirapine) to treat up to 21,000 people in Rwanda. The shipment, which took place on September 24th from Toronto, was approved under Canada's Access to Medicines Regime (CAMR), which was established in May 2004 to allow Canadian generic drug makers to produce patented drugs legally and to export them to developing countries using flexibilities in the World Trade Organization's TRIPS agreement. However, the CAMR process is complicated, and Apotex is the only company since its 2004 launch to have submitted a proposal and negotiated the CAMR process, receiving official approval in May (Scrip Online, May 9th, 2008). Apotex president Jack Kay described the process as "complex" and said "the regime must be changed… It is now up to the federal government to fix CAMR." Apotex is expected to provide a second shipment of seven million doses of Apo-TriAvir in September 2009. The company is completing the work on a humanitarian, not-for-profit basis.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel